People who base their health choices on what they found on the internet instead of talking to their doctors have long since been regarded with a generous amount of disdain. However, a new study suggests that using web-based counseling is actually just as effective at lowering blood pressure as taking actual medication.
The study was presented during the 66th Annual Scientific Session and Expo, which was held in Washington, D.C., The Washington Post reports. It looked at the cases of patients who enrolled in the website Heart and Stroke Association of Canada, where over 264 people diagnosed with high blood pressure and with an average age of 56 years old were tracked.
The groups were divided based on Web-based lifestyle counseling and Web-based control intervention, both of which involved different approaches to addressing systolic blood pressure. It would seem that the former method yielded better results than the latter, but both systems did accomplish the goal of reducing mmHg levels in the patients.
Robert P. Nolan from the Peter Munk Cardiac Center at the University Health Network is the lead author of the study and he calls web-based counseling e-Counseling. He confirmed that this method had similar results compared to having the patients take drugs in order to control their blood pressure.
“The electronic counseling (e-Counseling) intervention had an effect similar to that of adding an additional blood-pressure-lowering medication,” Prof. Nolan said.
As to what this so-called e-Counseling even involves, patients are given a variety of resources in order to help them cope with their health condition. These include interactive online content, as well as a few video and audio resources, MedicalXpress reports. Based on the results that the researchers got from the study, it would seem that the more engaging content yielded the best improvements in lowering blood pressure among the patients.


Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Samsung Bets Big on AI-Driven Chip Demand in 2025
Micron Technology Beats Q2 Earnings Estimates, Issues Strong AI-Driven Outlook
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Xiaomi's AI Model "Hunter Alpha" Mistaken for DeepSeek's Next Release
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets
Cyberattack on Stryker Triggers U.S. Government Warning Over Microsoft Intune Security 



